Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials

MLA

George F. Gao, et al. Safety and Immunogenicity of a Recombinant Tandem-Repeat Dimeric RBD Protein Vaccine against COVID-19 in Adults: Pooled Analysis of Two Randomized, Double-Blind, Placebo-Controlled, Phase 1 and 2 Trials. Dec. 2020. EBSCOhost, https://doi.org/10.1101/2020.12.20.20248602.

APA

George F. Gao, Chenfei Wang, Junhua Li, Siyu Tian, Changwei Wu, Yan Li, Xin Fang, Xian Yu, Xiang Zhao, Changgui Li, Lidong Gao, Fangjun Li, Shilong Yang, Lihong Liu, Shufang Meng, Yi Luo, Jinghua Yan, Zaixin Zhong, Yan Liu, … Lianpan Dai. (2020). Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials. https://doi.org/10.1101/2020.12.20.20248602

Chicago

George F. Gao, Chenfei Wang, Junhua Li, Siyu Tian, Changwei Wu, Yan Li, Xin Fang, et al. 2020. “Safety and Immunogenicity of a Recombinant Tandem-Repeat Dimeric RBD Protein Vaccine against COVID-19 in Adults: Pooled Analysis of Two Randomized, Double-Blind, Placebo-Controlled, Phase 1 and 2 Trials,” December. doi:10.1101/2020.12.20.20248602.